TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00639925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1-1084, VEGFR2-169, and gemcitabine
Description: One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
Study: NCT00588705

Intervention type: BEHAVIORAL
Intervention: focus group & questionaire
Description: The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
Study: NCT03090061

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Light induced fluorescence intraoral camera
Description: assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual-tactile assessment method according to FDI criteria
Description: assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
Study: NCT04276077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency electrical muscle stimulation training
Description: High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical muscle stimulation training
Description: Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
Study: NCT03692923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual community
Study: NCT05091996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-isometric muscle relaxation technique
Description: 1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
Study: NCT02702362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
Study: NCT04325165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Implantation
Description: Bilateral implantation of PPN DBS electrodes
Study: NCT02103699

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
Study: NCT03795285

Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of neutrophil CD64
Description: Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of neutrophil CD64
Description: Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
Study: NCT03635008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
Study: NCT02868840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: symptom management
Description: sending text message weekly to manage symptoms related to stroke
Study: NCT01028677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal spray with oxytocin
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
Study: NCT03635008

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
Study: NCT02112019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sialoendoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sialoendoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Study: NCT01784276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player.
Study: NCT02290847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (cognitive only version; CPT-C)
Description: CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (cognitive only version; CPT-C)
Description: CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (cognitive only version; CPT-C)
Description: CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
Study: NCT02797509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Skills-Based Intervention
Description: Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
Study: NCT01028677

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray without oxytocin
Description: 6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
Study: NCT02889185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTX1 IMAGIN EYE retinal camera
Description: In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
Study: NCT02744183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: Breakfast consumption

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain habitual habits
Description: Normal physical activity and dietary behaviors maintained
Study: NCT03778866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered handling medium
Description: The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
Study: NCT01146015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study: NCT00888797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol and Etodolac
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol and Etodolac
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
Study: NCT05969587

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% cysteamine cream
Description: 5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: hydroquinone cream group
Description: 4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
Study: NCT04755894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDDO-1756
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDDO-17561/HDDO-17562
Description: single dose
Study: NCT03183843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate
Description: Dabigatran Etexilate 150 mg capsules for oral administration twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin 2.5 mg tablets for oral administration once a day
Study: NCT03475758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: adding goserelin with chemotherapy
Study: NCT00156091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5- 20 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 or 10 mg BID

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT03139136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MBS2320
Description: As described in the arm descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As described in the arm descriptions
Study: NCT06212284

Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram 20mg
Description: Doses were delivered in gelatine capsules filled with microcrystalline cellulose.

Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram 20mg
Description: Doses were delivered in gelatine capsules filled with microcrystalline cellulose.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Doses were gelatine capsules filled with microcrystalline cellulose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Doses were gelatine capsules filled with microcrystalline cellulose
Study: NCT01462656

Intervention type: DRUG
Intervention: Non-EZG containing AED polytherapy
Description: AED polytherapy without EZG

Intervention type: DRUG
Intervention: EZG containing AED polytherapy
Description: AED polytherapy including EZG

Intervention type: DRUG
Intervention: Non-EZG AED monotherapy
Description: AED monotherapy without EZG

Intervention type: DRUG
Intervention: EZG AED monotherapy
Description: Any off-label use of EZG as monotherapy
Study: NCT00860080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL01
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Study: NCT00587795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StabilAir Wrist Brace
Description: Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placement of sugar tong splint or plaster cast
Description: Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
Study: NCT02347735

Intervention type: OTHER
Intervention: No interventions, only data collection
Description: Only data is collected from the subjects in both groups.

Intervention type: OTHER
Intervention: No interventions, only data collection
Description: Only data is collected from the subjects in both groups.
Study: NCT00783666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Description: Lactic Acid
Study: NCT03041766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
Study: NCT01023425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months
Study: NCT01951573

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
Study: NCT03041766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
Study: NCT00700024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim
Description: 50 mg/dose7day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: three times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT00777829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zolpidem
Description: Participants will receive one dose of 10 mg before each nap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: Participants will receive one dose of 10 mg before each nap.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a dose of placebo before each nap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a dose of placebo before each nap.
Study: NCT04502875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPP
Description: PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
Study: NCT00027807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.